Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Executive Summary

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Advertisement

Related Content

ReNeuron's Cell Therapies Attract Fosun Pharma, A Leading Regenerative Medicines Developer
Medigene Takes Center Stage In Roivant's Latest 'Vant'
Pipeline Watch: Phase III Starts With GLPG1690, Tislelizumab And PF-06482077
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard
Cutanea acquisition to bolster Maruho's US presence

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125049

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel